Abstract
The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.
Keywords: Angiotensin, prostate, bladder, kidney, angiogenesis, receptor
Reviews on Recent Clinical Trials
Title: Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Volume: 4 Issue: 2
Author(s): Akira Miyajima, Eiji Kikuchi, Takeo Kosaka and Mototsugu Oya
Affiliation:
Keywords: Angiotensin, prostate, bladder, kidney, angiogenesis, receptor
Abstract: The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.
Export Options
About this article
Cite this article as:
Miyajima Akira, Kikuchi Eiji, Kosaka Takeo and Oya Mototsugu, Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer, Reviews on Recent Clinical Trials 2009; 4 (2) . https://dx.doi.org/10.2174/157488709788185996
DOI https://dx.doi.org/10.2174/157488709788185996 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science Caveolin Involvement and Modulation in Breast Cancer
Mini-Reviews in Medicinal Chemistry PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Editorial
Current Medical Imaging Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers 3-Substituted Isocoumarins as Thymidine Phosphorylase Inhibitors
Letters in Drug Design & Discovery Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Treatment of High-Grade Pelvic-Type Serous Carcinomas (Ovary, Fallopian Tube and Peritoneum): Current Therapeutic Paradigms, Prospects, and Challenges
Current Cancer Therapy Reviews Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Editorial: Look for Changes in 2016
Current Molecular Medicine Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs